PL4152004T3 - Test wykrywający przeciwciała przeciwko wirusowi jc - Google Patents

Test wykrywający przeciwciała przeciwko wirusowi jc

Info

Publication number
PL4152004T3
PL4152004T3 PL22191259.5T PL22191259T PL4152004T3 PL 4152004 T3 PL4152004 T3 PL 4152004T3 PL 22191259 T PL22191259 T PL 22191259T PL 4152004 T3 PL4152004 T3 PL 4152004T3
Authority
PL
Poland
Prior art keywords
virus antibodies
antibodies test
test
virus
antibodies
Prior art date
Application number
PL22191259.5T
Other languages
English (en)
Inventor
Leonid Gorelik
Kenneth J. Simon
Meena Subramanyam
Mia Marie Rushe
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44305841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4152004(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of PL4152004T3 publication Critical patent/PL4152004T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL22191259.5T 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc PL4152004T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29404810P 2010-01-11 2010-01-11
US31619310P 2010-03-22 2010-03-22

Publications (1)

Publication Number Publication Date
PL4152004T3 true PL4152004T3 (pl) 2025-03-24

Family

ID=44305841

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17203178.3T PL3339865T3 (pl) 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc
PL11732315T PL2524060T3 (pl) 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc
PL22191259.5T PL4152004T3 (pl) 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL17203178.3T PL3339865T3 (pl) 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc
PL11732315T PL2524060T3 (pl) 2010-01-11 2011-01-11 Test wykrywający przeciwciała przeciwko wirusowi jc

Country Status (27)

Country Link
US (2) US9316641B2 (pl)
EP (4) EP4524571A3 (pl)
JP (2) JP5946218B2 (pl)
KR (1) KR101877576B1 (pl)
CN (1) CN102906278A (pl)
AU (1) AU2011203815B2 (pl)
BR (1) BR112012017014B1 (pl)
CA (1) CA2784137A1 (pl)
CY (2) CY1119972T1 (pl)
DK (3) DK4152004T3 (pl)
ES (3) ES3012733T3 (pl)
FI (2) FI4152004T3 (pl)
HR (3) HRP20250210T1 (pl)
HU (3) HUE036183T2 (pl)
IN (1) IN2012DN06139A (pl)
LT (3) LT3339865T (pl)
ME (1) ME03026B (pl)
MX (1) MX341991B (pl)
NO (1) NO2524060T3 (pl)
NZ (1) NZ600681A (pl)
PL (3) PL3339865T3 (pl)
PT (3) PT2524060T (pl)
RS (3) RS66509B1 (pl)
SG (2) SG181653A1 (pl)
SI (3) SI3339865T1 (pl)
SM (3) SMT202200445T1 (pl)
WO (1) WO2011085369A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031792A1 (en) 2005-04-04 2006-10-12 Meena Subramanyam Methods and products for evaluating an immune response to a therapeutic protein
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
CA2776756A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
ME03026B (me) 2010-01-11 2018-10-20 Biogen Ma Inc Test za antitijela protiv jc virusa
PL3575792T3 (pl) * 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)
WO2013087601A2 (en) * 2011-12-12 2013-06-20 Janssen Diagnostics Bvba Polyomavirus peptide sequences
US20130273549A1 (en) * 2012-04-16 2013-10-17 Board Of Regents, The University Of Texas System Detection of extracellular jcv micrornas
WO2013192100A1 (en) 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9949671B2 (en) 2013-03-13 2018-04-24 Orthoaccel Technologies, Inc. Diagnostic mouthpieces
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
US10955422B2 (en) 2014-02-27 2021-03-23 Biogen Ma, Inc. Method of assessing risk of PML
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
WO2019169317A1 (en) * 2018-03-02 2019-09-06 Stueve Olaf Methods and compositions for treating natalizumab-associated progressive multifocal encephalopathy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US5213796A (en) 1991-05-06 1993-05-25 Dana Farber Cancer Institute Assay for polyomavirus in humans and uses thereof
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
DE69329377T2 (de) 1992-03-10 2001-04-05 Quidel Corp., San Diego Trennmittel für rote blutkörperchen bei untersuchungen mit spezifischer bindung
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
WO2001027612A2 (de) 1999-10-12 2001-04-19 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
DE60043308D1 (de) 1999-12-16 2009-12-24 Biogen Idec Inc Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
CA2405448A1 (en) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2004511807A (ja) 2000-10-17 2004-04-15 ベッスト−テスト　アンパーツゼルスカブ 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
WO2003016902A1 (en) 2001-08-20 2003-02-27 Proteome Systems Intellectual Property Pty Ltd Diagnostic testing process and apparatus
ATE539816T1 (de) * 2001-08-20 2012-01-15 Proteome Systems Ltd Verfahren zum diagnostischen testen
US6605602B1 (en) 2001-09-28 2003-08-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method of treating BK virus nephropathy
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2490284C (en) 2002-06-21 2013-10-22 Mckesson Information Solutions Llc Closed loop medication use system and method
US20070275481A1 (en) 2003-11-24 2007-11-29 Biogen Idec Ma Inc. Methods For Detecting Half-Antibodies Using Chip Based Gel Electophoresis
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
AU2005265316B2 (en) 2004-07-08 2012-02-02 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP1833509A4 (en) 2004-12-03 2008-12-03 Biogen Idec Inc DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
WO2006112951A2 (en) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
CA3031792A1 (en) 2005-04-04 2006-10-12 Meena Subramanyam Methods and products for evaluating an immune response to a therapeutic protein
KR20080059268A (ko) 2005-09-29 2008-06-26 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는피리미디닐 아미드 화합물
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由ｖｌａ-４所調節的白血球黏附之嘧啶磺醯胺化合物
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP2009531304A (ja) * 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
DE602007009446D1 (de) * 2006-06-30 2010-11-11 Sumitomo Rubber Ind Gummizusammensetzung für Reifenlauffläche und Reifen mit daraus hergestellter Reifenlauffläche
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
BRPI1016273A2 (pt) 2009-02-05 2020-12-01 Biogen Idec Ma Inc. método para a detecção de polimavírus jc
WO2010096674A2 (en) 2009-02-20 2010-08-26 The Regents Of The University Of California A+ biomarker assays
ME03026B (me) * 2010-01-11 2018-10-20 Biogen Ma Inc Test za antitijela protiv jc virusa
PL3575792T3 (pl) 2011-05-31 2023-03-27 Biogen Ma Inc. Metoda oceny ryzyka postępującej wieloogniskowej leukoencefalopatii (pml)

Also Published As

Publication number Publication date
US10444234B2 (en) 2019-10-15
DK3339865T5 (da) 2023-03-20
JP2013516633A (ja) 2013-05-13
HRP20250210T1 (hr) 2025-04-11
PT3339865T (pt) 2022-11-22
DK4152004T3 (da) 2025-02-24
DK2524060T3 (en) 2018-03-12
SI2524060T1 (en) 2018-05-31
EP2524060B1 (en) 2017-11-29
SI4152004T1 (sl) 2025-04-30
AU2011203815B2 (en) 2015-11-26
ES2930469T3 (es) 2022-12-14
PL2524060T3 (pl) 2018-05-30
SG10201500079YA (en) 2015-03-30
US20130022961A1 (en) 2013-01-24
HRP20221390T1 (hr) 2023-01-06
EP4524571A2 (en) 2025-03-19
NO2524060T3 (pl) 2018-04-28
IN2012DN06139A (pl) 2015-09-18
BR112012017014A2 (pt) 2016-04-05
DK3339865T3 (da) 2022-11-28
ES2664173T3 (es) 2018-04-18
RS66509B1 (sr) 2025-03-31
ME03026B (me) 2018-10-20
CA2784137A1 (en) 2011-07-14
EP3339865B1 (en) 2022-08-24
CY1126069T1 (el) 2023-11-15
SMT202500065T1 (it) 2025-03-12
EP4524571A3 (en) 2025-06-11
JP2016040557A (ja) 2016-03-24
CN102906278A (zh) 2013-01-30
SG181653A1 (en) 2012-07-30
AU2011203815A1 (en) 2012-07-05
SMT201800148T1 (it) 2018-05-02
PL3339865T3 (pl) 2022-12-19
NZ600681A (en) 2014-10-31
EP4152004B1 (en) 2024-11-20
JP5946218B2 (ja) 2016-07-05
US9316641B2 (en) 2016-04-19
ES3012733T3 (en) 2025-04-10
FI3339865T5 (fi) 2023-04-15
EP3339865B9 (en) 2022-12-14
US20160187337A1 (en) 2016-06-30
HUE070903T2 (hu) 2025-07-28
CY1119972T1 (el) 2018-12-12
HK1255318A1 (en) 2019-08-16
KR101877576B1 (ko) 2018-07-12
SI3339865T1 (sl) 2023-01-31
EP2524060A4 (en) 2013-10-09
PT4152004T (pt) 2025-02-18
EP3339865A1 (en) 2018-06-27
MX2012007660A (es) 2012-07-25
LT2524060T (lt) 2018-03-26
SMT202200445T1 (it) 2023-01-13
RS63744B1 (sr) 2022-12-30
EP4152004B9 (en) 2025-04-09
FI3339865T3 (pl) 2022-11-30
EP2524060A1 (en) 2012-11-21
MX341991B (es) 2016-09-09
KR20120112621A (ko) 2012-10-11
EP4152004A1 (en) 2023-03-22
BR112012017014B1 (pt) 2021-07-20
HRP20180356T1 (hr) 2018-04-06
FI4152004T3 (fi) 2025-02-21
HUE060312T2 (hu) 2023-02-28
BR112012017014A8 (pt) 2018-06-05
PT2524060T (pt) 2018-03-28
WO2011085369A1 (en) 2011-07-14
RS56977B1 (sr) 2018-05-31
LT3339865T (lt) 2022-12-12
LT4152004T (lt) 2025-02-25
HUE036183T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
LTPA2019011I1 (lt) CGRP antikūnai
PL4152004T3 (pl) Test wykrywający przeciwciała przeciwko wirusowi jc
IL222272B (en) Anti-erbb3 antibodies
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
CY2017025I2 (el) Αντιδοτα αντιπηκτικων
DK3741883T5 (da) Antistofbiblioteker
DK3178851T3 (da) Anti-cd40-antistoffer
CO6791565A2 (es) Anticuerpos anti-notch1
PL3089450T3 (pl) Łączenie obszarów próbek
BR112013010688A2 (pt) anticorpos anti c-met
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
DK3275896T3 (da) Fremgangsmåde til at opnå antistoffer
EP2629796A4 (en) ANTIBODY
DK3202789T3 (da) Anti-vla-4-antistoffer
EP2578316A4 (en) PIPETTE
FI9224U1 (fi) Hiukkasten keräyslaite
FI20105301A0 (fi) Tarkastusluukku
FI20105294A0 (fi) Vesilukko